IMVT vs ACA Comparison

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Arcosa Inc is a manufacturer and producer of infrastructure-related products and solutions in the U.S. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. Maximum revenue is generated from the Construction Products segment, which produces aggregates, specialty materials, asphalt, and construction support gear. The Engineered Structures segment mainly manufactures and sells steel and concrete structures for infrastructure businesses, including utility structures for electricity transmission and distribution, structural wind towers, traffic and lighting structures, and telecommunication structures; and the Transportation Products segment builds inland barges, fiberglass covers, winches, marine hardware, and other industrial equipment.